Header links
Intranet
Dona
image/svg+xml Mapa
Contacte

Publicacions

Cercador de Publicacions

La producció científica dels nostres investigadors i investigadores és molt elevada. L'any 2022 es van publicar 1.629 articles a revistes científiques amb un factor d'impacte global que va superar els 15.000 punts.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

PMID: 29349598
Revista: INVESTIGATIONAL NEW DRUGS
Any: 2018
Referència: Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Adessi, Celine; Albanell, Joan; Cejalvo, Juan Miguel; Ceppi, Maurizio; Cervantes, Andres; Cortes, Javier; Dieras, Veronique; Gonzalez, Iria; Hasmann, Max; Jacob, Wolfgang et al.
DOI: 10.1007/s10637-018-0562-4

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

PMID: 30156984
Revista: JOURNAL OF CLINICAL ONCOLOGY
Any: 2018
Referència: J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29.
Factor d'impacte: 26.303
Tipus de publicació: Article en revista internacional
Autors: Ahn, Myung-Ju, Vansteenkiste, Johan F, Su, Wu-Chou, Felip, Enriqueta, Chia, Vincent, Glaser, Sabine, Pultar, Philippe, Zhao, Sylvia, Peng, Bin, Akimov, Mikhail et al.
DOI: 10.1200/JCO.2018.77.7326

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

PMID: 30156984
Revista: JOURNAL OF CLINICAL ONCOLOGY
Any: 2018
Referència: J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Ahn, Myung-Ju; Akimov, Mikhail; Chia, Vincent; Felip, Enriqueta; Glaser, Sabine; Kim, Dong-Wan; Lee, Dae Ho; Liu, Xiaoqing; Peng, Bin; Pultar, Philippe et al.
DOI: 10.1200/JCO.2018.77.7326

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors.

PMID: 29242283
Revista: ONCOLOGIST
Any: 2018
Referència: Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.
Factor d'impacte: 5.306
Tipus de publicació: Article en revista internacional
Autors: Lombard-Bohas, Catherine, Salazar, Ramon, Garcia-Carbonero, Rocio, Libutti, Steven K, Hendifar, Andrew E, Custodio, Ana, Guimbaud, Rosine, Capdevila, Jaume, Reed, Nicholas, Walenkamp, Annemiek et al.
DOI: 10.1634/theoncologist.2017-0144

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors.

PMID: 29242283
Revista: ONCOLOGIST
Any: 2018
Referència: Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Capdevila, Jaume; Custodio, Ana; Garcia-Carbonero, Rocio; Grande, Enrique; Guimbaud, Rosine; Hendifar, Andrew E; Klumpen, Heinz-Josef; Kong, Oliver; Libutti, Steven K; Lombard-Bohas, Catherine et al.
DOI: 10.1634/theoncologist.2017-0144

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

PMID: 29182496
Revista: JOURNAL OF CLINICAL ONCOLOGY
Any: 2018
Referència: J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.
Factor d'impacte: 26.303
Tipus de publicació: Article en revista internacional
Autors: Javle, Milind, Lowery, Maeve, Shroff, Rachna T, Weiss, Karl Heinz, Springfeld, Christoph, Bekaii-Saab, Tanios, Abou-Alfa, Ghassan K, Borad, Mitesh J, Ramanathan, Ramesh K, Goyal, Lipika et al.
DOI: 10.1200/JCO.2017.75.5009

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

PMID: 29182496
Revista: JOURNAL OF CLINICAL ONCOLOGY
Any: 2018
Referència: J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Abou-Alfa, Ghassan K; Bekaii-Saab, Tanios; Borad, Mitesh J; Borbath, Ivan; Chen, Li-Tzong; Choo, Su Pin; Ciombor, Kristen; El-Khoueiry, Anthony; Finn, Richard S; Goyal, Lipika et al.
DOI: 10.1200/JCO.2017.75.5009

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

PMID: 29198055
Revista: BREAST CANCER RESEARCH AND TREATMENT
Any: 2018
Referència: Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2.
Factor d'impacte: 3.605
Tipus de publicació: Article en revista internacional
Autors: Han, H S, Pistilli, B, Pluard, T, Urruticoechea, A, Farci, D, Kong, A, Bachelot, T, Chan, S, Robinson, D, Mouhaer, S L et al.
DOI: 10.1007/s10549-017-4596-7

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

PMID: 29198055
Revista: BREAST CANCER RESEARCH AND TREATMENT
Any: 2018
Referència: Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Bachelot, T; Chan, S; Farci, D; Han, H S; Jerusalem, G; Kong, A; Massacesi, C; Mouhaer, S L; Pistilli, B; Pluard, T et al.
DOI: 10.1007/s10549-017-4596-7

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

PMID: 29177953
Revista: Targeted Oncology
Any: 2018
Referència: Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9.
Factor d'impacte: 3.877
Tipus de publicació: Article en revista internacional
Autors: Lopez-Martin, Jose Antonio, Martin-Liberal, Juan, Lopez-Pousa, Antonio, Martinez-Trufero, Javier, Martin-Broto, Javier, Cubedo, Ricardo, Lavernia, Javier, Redondo, Andres, Tirado, Oscar M, Garcia-Del-Muro, Xavier et al.
DOI: 10.1007/s11523-017-0539-9

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

PMID: 29177953
Revista: Targeted Oncology
Any: 2018
Referència: Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Cubedo, Ricardo; Garcia-Del-Muro, Xavier; Lavernia, Javier; Lopez-Martin, Jose Antonio; Lopez-Pousa, Antonio; Martin-Broto, Javier; Martin-Liberal, Juan; Martinez-Trufero, Javier; Mulet-Margalef, Nuria; Redondo, Andres et al.
DOI: 10.1007/s11523-017-0539-9

Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

PMID: 29793946
Revista: CLINICAL CANCER RESEARCH
Any: 2018
Referència: Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.
Factor d'impacte: 10.199
Tipus de publicació: Article en revista internacional
Autors: Dickler, Maura N, Saura, Cristina, Richards, Donald, Krop, Ian, Cervantes, Andres, Bedard, Phillipe L, Patel, Manish R, Pusztai, Lajos, Oliveira, Mafalda, Cardenas, Alison K et al.
DOI: 10.1158/1078-0432.CCR-18-0613

Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

PMID: 29793946
Revista: CLINICAL CANCER RESEARCH
Any: 2018
Referència: Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Baselga, Jose; Bedard, Phillipe L; Cardenas, Alison K; Cervantes, Andres; Cui, Na; Dickler, Maura N; Hsu, Jerry Y; Krop, Ian; Oliveira, Mafalda; Patel, Manish R et al.
DOI: 10.1158/1078-0432.CCR-18-0613

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.

PMID: 29506988
Revista: CLINICAL CANCER RESEARCH
Any: 2018
Referència: Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.
Factor d'impacte: 10.199
Tipus de publicació: Article en revista internacional
Autors: Penuel, Elicia, Hill, Andrew Graham, Findlay, Michael, Burge, Matthew, Jackson, Christopher, Garcia Alfonso, Pilar, Samuel, Leslie, Ganju, Vinod, Karthaus, Meinolf, Amatu, Alessio et al.
DOI: 10.1158/1078-0432.CCR-17-0646

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.

PMID: 29506988
Revista: CLINICAL CANCER RESEARCH
Any: 2018
Referència: Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Amatu, Alessio; Bridgewater, John; Burge, Matthew; Coveler, Andrew L; Di Bartolomeo, Maria; Findlay, Michael; Ganju, Vinod; Garcia Alfonso, Pilar; Hanley, William; Hidalgo, Manuel et al.
DOI: 10.1158/1078-0432.CCR-17-0646

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

PMID: 29756206
Revista: INTERNATIONAL JOURNAL OF CANCER
Any: 2018
Referència: Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9.
Factor d'impacte: 7.36
Tipus de publicació: Article en revista internacional
Autors: Verslype, Chris, Raymond, Eric, Cubillo, Antonio, Schueler, Armin, Zhao, Charles, Hammel, Pascal, Radenkovic, Dejan, Manojlovic, Nebojsa, Bazin, Igor, Van Cutsem, Eric et al.
DOI: 10.1002/ijc.31603

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

PMID: 29756206
Revista: INTERNATIONAL JOURNAL OF CANCER
Any: 2018
Referència: Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Bazin, Igor; Canon, Jean-Luc; Cubillo, Antonio; Hammel, Pascal; Hidalgo, Manuel; Macarulla, Teresa; Manojlovic, Nebojsa; Poddubskaya, Elena; Radenkovic, Dejan; Raymond, Eric et al.
DOI: 10.1002/ijc.31603

PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.

PMID: 29339541
Revista: CANCER RESEARCH
Any: 2018
Referència: Cancer Res. 2018 Apr 1;78(7):1805-1819. doi: 10.1158/0008-5472.CAN-17-1346. Epub 2018 Jan 16.
Factor d'impacte: 9.13
Tipus de publicació: Article en revista internacional
Autors: Dopeso, Higinio, Jiao, Hui-Ke, Cuesta, Angel M, Henze, Anne-Theres, Jurida, Liane, Kracht, Michael, Acker-Palmer, Amparo, Acker, Till, Garvalov, Boyan K et al.
DOI: 10.1158/0008-5472.CAN-17-1346

PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.

PMID: 29339541
Revista: CANCER RESEARCH
Any: 2018
Referència: Cancer Res. 2018 Apr 1;78(7):1805-1819. doi: 10.1158/0008-5472.CAN-17-1346. Epub 2018 Jan 16.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Acker, Till; Acker-Palmer, Amparo; Cuesta, Angel M; Dopeso, Higinio; Garvalov, Boyan K; Henze, Anne-Theres; Jiao, Hui-Ke; Jurida, Liane; Kracht, Michael et al.
DOI: 10.1158/0008-5472.CAN-17-1346

Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.

PMID: 29691292
Revista: CLINICAL CANCER RESEARCH
Any: 2018
Referència: Clin Cancer Res. 2018 Aug 1;24(15):3767-3780. doi: 10.1158/1078-0432.CCR-18-0177. Epub 2018 Apr 24.
Factor d'impacte: 10.199
Tipus de publicació: Article en revista internacional
Autors: Veiga, Sonia Rosa, Ge, Xuemei, Mercer, Carol A, Hernandez-Alvarez, Maria Isabel, Thomas, Hala Elnakat, Hernandez-Losa, Javier, Ramon Y Cajal, Santiago, Zorzano, Antonio, Thomas, George, Kozma, Sara C et al.
DOI: 10.1158/1078-0432.CCR-18-0177

Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR.

PMID: 32177313
Revista: ANNALS OF ONCOLOGY
Any: 2018
Referència: Ann Oncol. 2018 Jun;29 Suppl 5:v91. doi: 10.1093/annonc/mdy151.323. Epub 2020 Jan 7.
Factor d'impacte: 13.926
Tipus de publicació: Carta o abstract
Autors: Veiga, S, Ge, X, Mercer, C, Hernandez-Alvarez, M, Thomas, H, Hernandez-Losa, J, Cajal, S R Y, Zorzano, A, Thomas, G, Kozma, S et al.
DOI: 10.1093/annonc/mdy151.323

Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.

PMID: 29691292
Revista: CLINICAL CANCER RESEARCH
Any: 2018
Referència: Clin Cancer Res. 2018 Aug 1;24(15):3767-3780. doi: 10.1158/1078-0432.CCR-18-0177. Epub 2018 Apr 24.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Ge, Xuemei; Hernandez-Alvarez, Maria Isabel; Hernandez-Losa, Javier; Kozma, Sara C; Mercer, Carol A; Ramon Y Cajal, Santiago; Thomas, George; Thomas, Hala Elnakat; Veiga, Sonia Rosa; Zorzano, Antonio et al.
DOI: 10.1158/1078-0432.CCR-18-0177

Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR.

PMID: 32177313
Revista: ANNALS OF ONCOLOGY
Any: 2018
Referència: Ann Oncol. 2018 Jun;29 Suppl 5:v91. doi: 10.1093/annonc/mdy151.323. Epub 2020 Jan 7.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Cajal, S R Y; Ge, X; Hernandez-Alvarez, M; Hernandez-Losa, J; Kozma, S; Mercer, C; Thomas, G; Thomas, H; Veiga, S; Zorzano, A et al.
DOI: 10.1093/annonc/mdy151.323

Phenotype-modifying Factors in Hypertrophic Cardiomyopathy.

PMID: 29844006
Revista: REVISTA ESPANOLA DE CARDIOLOGIA
Any: 2018
Referència: Rev Esp Cardiol (Engl Ed). 2018 Sep;71(9):770. doi: 10.1016/j.rec.2018.03.021. Epub 2018 May 26.
Factor d'impacte: 5.166
Tipus de publicació: Carta o abstract
Autors: Limeres Freire, Javier et al.
DOI: 10.1016/j.rec.2018.03.021